1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99909
    Elranatamab

    埃纳妥单抗

    Elranatamab (PF-06863135) 是一种抗 CD3E/TNFRSF17 的人源 IgG2κ 单克隆抗体。Elranatamab 的同型对照产品:Human IgG2 kappa, Isotype Control (HY-P99002)。
    Elranatamab
  • HY-P9989
    Linvoseltamab

    利伏赛坦单抗

    Inhibitor 99.71%
    Linvoseltamab 是一种双特异性抗体,靶向 BCMA (TNFRSF17) 和 CD3 epsilon。Linvoseltamab 在复发/难治性多发性骨髓瘤 (RRMM) 模型中显示出安全性和令人鼓舞的效力。
    Linvoseltamab
  • HY-P99249
    Vonlerolizumab

    珀伽利珠单抗

    Inhibitor 99.70%
    Vonlerolizumab (MOXR 0916) 是一种人源化的 IgG 激动的 OX40 特异性单克隆抗体。Vonlerolizumab 可用于癌症的研究。
    Vonlerolizumab
  • HY-128754
    Monoolein Inhibitor 99.91%
    Monoolein 是一种具有生物相容性的脂质分子,可作为载体用于骨修复。Monoolein 具有抗炎活性,可抑制 LPS (HY-D1056) 诱导的免疫反应。Monoolein 通过减少免疫反应因子 (如 IL-12 p40, IL-6, 和 TNF-α) 的产生,并抑制 NO 的生成,来发挥抗炎作用。Monoolein 可用于药物递送和炎症疾病领域的研究。
    Monoolein
  • HY-112275
    TNF-α-IN-1 Inhibitor 99.42%
    TNF-α-IN-1是 TNF-α 抑制剂,来自专利 US20030096841A1,化合物实例 I-7。
    TNF-α-IN-1
  • HY-18377
    Bioymifi Activator ≥98.0%
    Bioymifi 是一种有效的 TRAIL 受体 DR5 激活剂,与DR5的胞外结构域 (ECD) 结合,Kd 为 1.2 μM,Bioymifi 可作为单一的诱导剂诱导 DR5 的聚集,导致细胞凋亡。
    Bioymifi
  • HY-N0261
    Aurantio-obtusin

    橙黄决明素

    Inhibitor 99.89%
    Aurantio-obtusin 是一种可以从决明子中提取的蒽醌类化合物。Aurantio-obtusin 具有降血压、降血脂和抗炎的作用。Aurantio-obtusin 是一种口服有效的血管扩张剂。Aurantio-obtusin 通过 AMPK/自噬和 AMPK/TFEB 介导的脂质积累抑制的途径来改善肝脂肪 变性 。
    Aurantio-obtusin
  • HY-N3021
    D-chiro-Inositol

    D-手性肌醇

    Inhibitor ≥98.0%
    D-chiro-Inositol 是一种肌醇的差向异构体,具有改善糖代谢、抗肿瘤、抗炎和抗氧化的活性。D-chiro-Inositol 通过改善胆汁酸分泌和减轻氧化应激,有效缓解胆汁淤积。它通过模拟胰岛素的作用来改善胰岛素抵抗,降低高血糖和循环胰岛素水平,减少血清雄激素,并改善 X 综合征的一些代谢异常。此外,D-chiro-Inositol 可诱导促炎因子 (如 Nf-κB) 和细胞因子 (如 TNF-α) 的减少,从而发挥抗炎作用。D-chiro-Inositol 可用于肝硬化、乳腺癌、2 型糖尿病和多囊卵巢综合征的研究。
    D-chiro-Inositol
  • HY-139066
    Punicic acid Inhibitor ≥98.0%
    Punicic acid 是石榴籽油的一种生物活性化合物。Punicic acid 是共轭 α-亚麻酸和 ω-5多不饱和脂肪酸的异构体。Punicic acid 具有抗炎和抗氧化活性,能够抑制炎症介质如肿瘤坏死因子α (TNF-α) 的表达。Punicic acid 还可以通过增加 GLUT4 蛋白的表达和抑制 calpain 的过度激活来减少 β-淀粉样蛋白 (Amyloid-β) 沉积的形成和tau 的过度磷酸化,用于预防和治疗神经退行性疾病。此外,Punicic acid 也具有依赖于脂质过氧化和 PKC 途径的乳腺癌抑制剂特性。
    Punicic acid
  • HY-N2055
    Kaempferol 3-O-sophoroside Inhibitor 99.84%
    Kaempferol 3-O-sophoroside 是一种具有口服活性的 Kaempferol 的衍生物。Kaempferol 3-O-sophoroside 具有抗炎、镇痛和抗抑郁的作用。Kaempferol 3-O-sophoroside 是 HMGB1 (High mobility group box 1) 的细胞表面受体 toll 样受体 (TLR) 2/4 的抑制剂 ,也可以通过阻止 NF-κB 的表达激活和 TNF-α 的产生而发挥抗炎作用。Kaempferol 3-O-sophoroside 通过结合 AMP 活化蛋白激酶 (AMPK) 促进脑源性神经营养因子 (BDNF) 的产生和自噬增强,发挥抗抑郁作用。 Kaempferol 3-O-sophoroside 有望用于炎症与神经疾病领域研究。
    Kaempferol 3-O-sophoroside
  • HY-N2086
    Ethyl palmitate

    棕榈酸乙酯

    Inhibitor 99.05%
    Ethyl palmitate (Ethyl hexadecanoate) 是一种 CHIKV 病毒抑制剂,EC50 值为 0.0068 μM。Ethyl palmitate 可以降低内毒素血症大鼠中的 TNF-αIL-6NF-κB 水平,具有抗炎活性。
    Ethyl palmitate
  • HY-15643A
    LY 303511 hydrochloride Activator 98.87%
    LY 303511 hydrochloride 是 是 LY294002 的一种结构类似物,但 LY303511 不抑制 PI3K。LY303511 可增强 SHEP-1 神经母细胞瘤细胞的TRAIL 敏感性。LY303511 可逆地阻断 MIN6 胰岛瘤细胞中的 K+ 电流 (IC50=64.6±9.1 μM)。
    LY 303511 hydrochloride
  • HY-12557
    γ-Glutamylvaline Inhibitor 99.73%
    γ-Glutamylvaline 是一种 CaSR 的激活剂,具有抗炎活性。γ-Glutamylvaline 能够抑制 TNF-α 诱导的促炎细胞因子的产生,并增加 Wnt5a 表达。γ-Glutamylvaline 激活 3T3-L1 小鼠脂肪细胞中的钙敏感受体途径预防低度慢性炎症。
    γ-Glutamylvaline
  • HY-P99149
    Anti-Mouse TNFR2 Antibody (TR75-54.7) Inhibitor
    Anti-Mouse TNFR2 Antibody 是抗小鼠 TNFR2 的 IgG 抗体抑制剂,宿主是 Armenian Hamster。
    Anti-Mouse TNFR2 Antibody (TR75-54.7)
  • HY-N9445
    Lacto-N-neotetraose 99.71%
    Lacto-N-neotetraose (LNnT) 是一种内源性代谢物 (endogenous metabolite)。Lacto-N-neotetraose 可以抑制 TNF-α 诱导的未成熟上皮细胞中的 IL-8 分泌。Lacto-N-neotetraose 具有抗炎活性,可提高伤口愈合能力。
    Lacto-N-neotetraose
  • HY-154821A
    DRI-C21041 (DIEA) Inhibitor
    DRI-C21041 DIEA 是一种 CD40/CD40L 相互作用抑制剂,IC50 值为 0.31 μM。DRI-C21041 DIEA 抑制由同种异体抗原诱导的免疫反应。
    DRI-C21041 (DIEA)
  • HY-15507
    VGX-1027 Inhibitor 99.76%
    VGX-1027 是一种口服有效的异恶唑化合物,具有免疫调节特性。VGX-1027 靶向巨噬细胞,减少促炎性介质 TNF-α,IL-1β,IL-10 的产生。VGX-1027 通过限制细胞因子介导的免疫炎症而具有抗糖尿病作用。
    VGX-1027
  • HY-118250
    GSK2245035 Activator 99.85%
    GSK2245035 是一种高效的,选择性的鼻内 Toll-Like 受体 7 (TLR7) 激动剂,具有优先刺激 1 型干扰素 (IFN) 的特性。GSK2245035 对 IFNα 和TNFα 的 pEC50 分别为 9.3 和 6.5。GSK2245035 有效抑制人外周血细胞培养物中过敏原诱导的 Th2 细胞因子产生。GSK2245035 有用于哮喘的潜力。
    GSK2245035
  • HY-P99812
    Ragifilimab

    拉格芙利单抗

    Agonist
    Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。
    Ragifilimab
  • HY-W082785A
    L6H21 Inhibitor 99.46%
    L6H21 是 Chalcone (HY-121054) 衍生物,是一种口服有效的特异性骨髓分化蛋白 (MD-2) 抑制剂。L6H21 高亲和力地直接与 MD-2 蛋白结合,KD 值为 33.3 μM,阻断 LPS-TLR4/MD-2 复合物形成。L6H21 抑制 LPS 诱导的 RAW264.7 巨噬细胞中 TNF-α IL-6 的表达,IC50 分别为 6.58 和 8.59 μM。L6H21 可用于酒精性肝病、代谢紊乱和神经炎症的研究。
    L6H21
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.